Previous in-vitro and in-vivo clinical studies have proven that anti-PSMA CAR-T cells effectively target lesions or cells with PSMA expression [54,55] and provided a valuable rationale for the continuous evaluation of PSMA-targeting modalities for PCa management. Here, FOLH1 is linked to posterior cortical atrophy.